The Enterprise Value as of September 2024 (TTM) for Dyne Therapeutics, Inc. (DYN) is 2.73B

According to Dyne Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.73B. This represents a change of 85.58% compared to the average of 1.47B of the last 4 quarters.

Dyne Therapeutics, Inc. (DYN) Historical Enterprise Value (quarterly & annually)

How has DYN Enterprise Value performed in the past?

The mean historical Enterprise Value of Dyne Therapeutics, Inc. over the last ten years is 4.32B. The current 2.73B Enterprise Value has changed 6.23% with respect to the historical average. Over the past ten years (40 quarters), DYN's Enterprise Value was at its highest in in the June 2017 quarter at 12.74B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

Dyne Therapeutics, Inc. (DYN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Dyne Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dyne Therapeutics, Inc. (DYN) Average Enterprise Value

How has DYN Enterprise Value performed in the past?

The current Enterprise Value of Dyne Therapeutics, Inc. (DYN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Dyne Therapeutics, Inc. (DYN) Enterprise Value vs. Peers

How is DYN’s Enterprise Value compared to its peers?

Dyne Therapeutics, Inc.’s Enterprise Value is greater than Stoke Therapeutics, Inc. (586.20M), greater than Pliant Therapeutics, Inc. (762.35M), less than Cytokinetics, Incorporated (6.96B), less than Revolution Medicines, Inc. (6.80B), greater than Edgewise Therapeutics, Inc. (1.60B), greater than Cullinan Oncology, Inc. (930.13M), greater than Mineralys Therapeutics, Inc. (490.57M), greater than DICE Therapeutics, Inc. (2.21B), less than Karuna Therapeutics, Inc. (12.43B), less than Gracell Biotechnologies Inc. (5.45B), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Monte Rosa Therapeutics, Inc. (284.72M), greater than Design Therapeutics, Inc. (221.42M), greater than Erasca, Inc. (689.13M),

Build a custom stock screener for Dyne Therapeutics, Inc. (DYN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyne Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dyne Therapeutics, Inc. (DYN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dyne Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.